Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2024-11-26 00:00:00 ET · period of report 2024-11-22 · accession 0001867096-24-000190 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-11-26 | 2024-11-22 | XERS | Pieper Steven | See Remarks | M - OptEx | $1.55 | +19.5K | 1.44M | +1% | +$30.2K |
| DM | 2024-11-26 | 2024-11-22 | XERS | Pieper Steven | See Remarks | M - OptEx | $0.00 | -19.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-22 | M | A | 19,483 | $1.55 | 1,441,820 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-11-22 | M | D | 16,843 | $0.00 | 0 | D | $1.55 · — to 2027-02-04 | 16,843 Common Stock | (F1) The reporting person received the stock options on February 7, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. The options vested in four equal installments on February 2018, 2019, 2021, and 2021. |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-11-22 | M | D | 2,640 | $0.00 | 0 | D | $1.55 · — to 2027-06-12 | 2,640 Common Stock | (F2) The reporting person received the stock options on June 12, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. The options vested in four equal installments on June 2018, 2019, 2021, and 2021. |